CoChat

Risk/Benefit Assessment of β-Blockers and Diuretics Precludes Their Use for First-Line Therapy in Hypertension

Open access
Messerli, Franz H., Bangalore, Sripal, Julius, Stevo · 2008 · Circulation
Cited by 132

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

S ystemic arterial hypertension affects 72 million US adults and an additional hundreds of millions of persons worldwide.1,2 Most of these are candidates for pharmacological treatment to reduce risk of cardiovascular disease (CVD) events, based primarily on a very large body of epidemiological and intervention research in humans.Because of this high prevalence and the cardiovascular consequences of untreated or inadequately treated hypertension, the selection of drugs for initial and continuing, long-term treatment has large public health and economic implications.Fortunately, such decisions and the expert recommendations that seek to guide them can call on evidence from 4 decades of randomized multicenter clinical trials evaluating effects of treatment on clinical CVD.We summarize that evidence in this article, in approximate chronological order, and we comment on the related treatment guidelines.We close with some of the major clinical questions yet to be resolved.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.107.695007

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 132

Metadata

Authors
Messerli, F. H., Bangalore, S., & Julius, S.
Venue
Circulation
Published
2008-05-20
Volume
117
Issue
20
Pages
2706-2715
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2130513215
Cited by
132
References
7
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risk/Benefit Assessment of β-Blockers and Diuretics Precludes Their Use for First-Line Therapy in Hypertension. https://app.cochat.ai/papers/10.1161/circulationaha.107.695007
The paper
Messerli, F. H., Bangalore, S., & Julius, S. (2008). Risk/Benefit Assessment of β-Blockers and Diuretics Precludes Their Use for First-Line Therapy in Hypertension. Circulation. https://doi.org/10.1161/circulationaha.107.695007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.